FDA accepts Roclatan new drug application

The FDA has accepted Aerie Pharmaceuticals’ new drug application for its once-daily IOP-lowering eye drop Roclatan, the company announced in a press release.
Roclatan, a fixed-dose combination of netarsudil and latanoprost to lower IOP in patients with glaucoma or ocular hypertension, received “day 74” notification from the FDA earlier than expected, and a Prescription Drug User Fee Act date has been set for March 14, 2019, the release said.
“We are delighted with this positive news on our Roclatan NDA, and if approved, we expect to be fully prepared to (Read more...)

Full Story →